 |
Twice-Weekly Briefing
Friday, November 6, 2026
Issue 261106-78
|
|
|
The MOC Brief
Health policy, priced and translated for self-funded plan sponsors
|
|
In This Edition
Five developments, and what each one costs you.
| 1. | Six employers took their third party administrator to court on October 20 and asked for an order releasing their plan claims data | | 2. | The annual gag clause attestation falls due again, and for a self-funded plan the legal duty to file stays with the plan even when a service provider files for it | | 3. | Thirty-eight percent of insulin fills in employer coverage cost the member more than thirty-five dollars for a month's supply in 2023, down from fifty-two percent in 2019 | | 4. | CVS says it intends to separate into two public companies, which would put the pharmacy benefit manager and the mail pharmacy under different owners | | 5. | A federal brief explains why the rebate your plan was contractually owed is typically not required when a covered entity buys the drug at the 340B price |
|
|
| 1 · FIDUCIARY LITIGATION · October 20, 2026 |
| Six Employers Sued UnitedHealth Over Claims Handling and Asked a Court to Order Their Plan Data Released |
| Aramark, Whirlpool, W.W. Grainger, Kraft Heinz, Ralph Lauren and Sterling Jewelers filed suit in the Eastern District of Texas on October 20, 2026, together with their health plans and, for four of the six, a benefits committee or board, for 23 named plaintiffs in all. The case is No. 2:26-cv-00949-JRG, and the version on the public docket is Document 3, a redacted 62 page complaint carrying a certificate that a motion to seal has been filed. Six defendants are named, among them UnitedHealth Group, United Medical Resources and HealthScope Benefits. The complaint pleads 12 claims, including fiduciary breach and prohibited transactions under ERISA, breach of contract, gross negligence and unjust enrichment, and it says United has served as third party administrator of these plans since at least 2020. On cross plan offsetting the plaintiffs allege that United overpays a provider using one plan's funds, then recovers the overpayment by deducting it from the next payment owed that provider, which often comes from a different plan, so the plan that overpaid is never made whole. They allege that offsetting payment most often came from United's own fully insured business. Among the relief sought is a preliminary injunction compelling United to provide all plan claims data, subject to privacy protections. |
|
MOC Perspective
Nothing here has been decided. A complaint is one side's untested allegations, no court has weighed them, and the plaintiffs put no dollar figure on their own losses anywhere in the document. What should hold your attention is the relief these companies went to court for, which is their own claims data. If employers this size concluded they had to sue to get it, the clause in your own administrative services agreement that governs data access is worth reading before you renew.
What to do now
| ▪ | Pull your administrative services agreement, find the clause that governs claims data access, and request the underlying data in writing within 30 days. | | ▪ | Ask your administrator in writing whether it applies cross plan offsetting to your plan, and set a 15 business day deadline for the reply. | | ▪ | Check whether any of the six defendants named in this case touches your plan, including HealthScope Benefits as a subcontracted administrator. |
|
|
| Source: Complaint, Aramark Services, Inc. et al. v. United Health Group Incorporated et al., No. 2:26-cv-00949-JRG (E.D. Tex.), redacted public version as posted by Benefits Digest |
|
| 2 · GAG CLAUSE ATTESTATION · December 31, 2026 |
| Your Gag Clause Attestation Comes Due at Year End and a Self-Funded Plan Keeps the Legal Duty to File |
| The annual attestation that your plan is free of gag clauses falls due on December 31, 2026. The rule comes from a joint FAQ issued by Labor, Health and Human Services and the Treasury on February 23, 2023, which set the first filing at the end of 2023 and said subsequent attestations, covering the period since the last preceding attestation, are due by December 31 of each year thereafter. Both fully insured and self-funded group health plans have to file, and filing goes through a CMS web portal. A vendor may file on your behalf, but the agencies were explicit that where a self-funded plan arranges for a service provider to attest, the legal requirement to provide a timely attestation remains with the plan. Plans that miss the deadline may be subject to enforcement action. Plans made up only of health reimbursement arrangements or other account based plans are covered by enforcement discretion rather than an exemption, and for a fully insured plan the issuer's filing satisfies the requirement. |
|
MOC Perspective
This is eight weeks out and it is the kind of deadline that gets missed because somebody assumed the administrator had it. Get that assumption confirmed in writing, because the agencies put the exposure on a self-funded plan and not on the vendor. The substance behind the filing is worth a look too. The FAQ gives, as an example of a prohibited gag clause, a contract term making your access to provider specific cost and quality information dependent on the administrator's discretion.
What to do now
| ▪ | Confirm by December 1 whether your administrator is filing your attestation or whether you file it yourself, and get that answer in writing. | | ▪ | File through the CMS portal before December 31 if no service provider has agreed in writing to do it for you. | | ▪ | Read your top 3 network and administrative agreements for terms that leave your access to provider specific cost and quality data at a vendor's discretion. |
|
|
| Source: Labor, Health and Human Services and the Treasury, FAQs About Affordable Care Act and Consolidated Appropriations Act, 2021 Implementation Part 57, February 23, 2023 |
|
| 3 · MEMBER DRUG COSTS · November 3, 2026 |
| Forty-One Percent of Insulin Users in Employer Coverage Averaged Over $35 for a 30-Day Supply in 2023 |
| The Health Care Cost Institute reported on November 3, 2026 that 41 percent of insulin users with employer sponsored insurance spent over $35 out of pocket on average for a 30 day supply in 2023, down from over 58 percent in 2019. Measured by prescription rather than by person, 38 percent of insulin fills cost more than $35 for a 30 day supply in 2023, down from 52 percent in 2019. The analysis drew on the institute's own commercial claims data, and the sample for that measure included people enrolled in employer sponsored insurance for at least one month during 2019 through 2023 who were under 65 and filled at least one insulin prescription, weighted to be representative of use rates across the national employer insured population. It did not restrict the sample to people with a diabetes diagnosis, and it reports no figures after 2023. The institute grouped out of pocket costs into five bands, from $35 or less up to more than $200. |
|
MOC Perspective
Note which caps the institute names. Congress capped Part D insulin cost sharing in 2022, more than half the states have capped it for state regulated commercial coverage, and two Senate bills would reach all commercial plans. None of those caps reaches a self-funded plan on its own, so what your members pay at the counter is set by your plan design. The figure this analysis cannot give you is your own, and that is the one to go and ask for.
What to do now
| ▪ | Ask your pharmacy benefit administrator for the out of pocket distribution on your plan's 2026 insulin fills, by cost band rather than as an average. | | ▪ | Compare the answer against the 38 percent of insulin fills the institute reported for employer coverage, and ask separately for the same measure counted per user rather than per fill. | | ▪ | Decide before January 1 whether your next plan year caps member insulin cost sharing, and price the change against your current spread. |
|
|
| Source: Health Care Cost Institute, Over 40% of Insulin Users with ESI Spend More Than $35 Out-of-pocket on 30-day Supply of Insulin |
|
| 4 · PHARMACY STRUCTURE · November 4, 2026 |
| CVS Says It Intends to Split in Two and Put Caremark and the Mail Pharmacy Under Different Owners |
| CVS Health said on November 4, 2026 that it intends to separate into two independent, publicly traded companies. One, keeping the CVS Health name for now, comprises Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The other, to be named CVS Pharmacy, comprises approximately 9,000 CVS pharmacies, the mail pharmacy, MinuteClinic including virtual care, and the Health100 technology services business. The company said it had a leading pharmacy benefit manager with approximately 87 million plan members as of September 30, 2026, a figure it attributes to the whole company rather than to Caremark by name. Completion is expected in the first half of 2028, subject to customary conditions including, among others, final board approval, an effective Form 10 registration statement and confirmation of tax free treatment. CVS said customers, patients and clients will continue to receive their medicine, care, benefits and services uninterrupted, and that CVS Pharmacy would pursue a wider set of partnerships across the health care system, including with payers, pharmacy benefit managers and manufacturers. |
|
MOC Perspective
Read the two lists again and notice where the mail pharmacy went. If the separation closes as announced and Caremark administers your pharmacy benefit, the company processing your claims and the company dispensing your members' mail order prescriptions end up under different owners, and the second one says it intends to pursue partnerships with pharmacy benefit managers generally rather than only the one it is leaving. Nothing changes on the company's own timetable before 2028, and the announcement names no contract terms at all. The work is in your renewal paperwork, not in your pharmacy.
What to do now
| ▪ | Ask your pharmacy benefit manager in writing which of the two companies will hold your mail pharmacy obligations, and get the answer before your pharmacy contract renews. | | ▪ | Add assignment and change of control language to your pharmacy contract review, and set a diligence date 90 days before your renewal. | | ▪ | Price your mail order channel separately from your retail network at renewal, because the two sit under different owners once the split closes in 2028. |
|
|
| Source: CVS Health, CVS Health announces intent to create two distinct leaders in healthcare |
|
| 5 · DRUG DISCOUNTS · October 8, 2026 |
| A Federal Brief Says Drugmakers Are Typically Not Required to Pay Your Plan Rebates on 340B Purchases |
| A brief published by the HHS Office of the Assistant Secretary for Planning and Evaluation on October 8, 2026 sets out a mechanism worth knowing if your plan pays pharmacy claims. To prevent duplicate discounts, the brief states, manufacturers are typically not required to provide otherwise contractually obligated rebates to self-funded employers when covered entities purchase drugs at the 340B discounted price. The brief, titled Mission vs. Margin, is written by Aiden Lee, Khrysta A. Dunkel, Eden Volkov, Sebastian Askar, Casey B. Mulligan and Ge Bai. It puts 340B drug sales, which its own figure labels covered entity purchases, at $12 billion in 2015 rising to $81 billion in 2024, with the majority of growth coming from hospitals. It glosses the spread a covered entity earns as the margin between the discounted 340B price and the reimbursement rate the entity receives. Separately, CMS has proposed reimbursing hospitals and most integrated hospital outpatient departments for 340B acquired drugs at average sales price less 33.4 percent, a Medicare outpatient rate that would take effect in 2027 if the rule is finalized. |
|
MOC Perspective
The exposure is simple, and it is the kind that does not show up as a line item. Your plan pays the claim at the negotiated rate while the rebate you were contractually owed on that same drug does not arrive. The brief names no fix for plan sponsors; its conclusion says only that reform to Medicare outpatient payment, if adopted, could realign the program's incentives. What you can act on sits in your rebate guarantee and in knowing which of your network hospitals are covered entities.
What to do now
| ▪ | Ask your pharmacy benefit manager to report what share of your 2026 clinician administered drug claims were filled with 340B acquired product. | | ▪ | Read your rebate guarantee for language excluding 340B acquired drugs from the guaranteed amount, and raise it before you sign for 2027. | | ▪ | Ask which of your top 10 network hospitals by spend are 340B covered entities, and put the answer beside your site of care differentials. |
|
|
| Source: HHS Office of the Assistant Secretary for Planning and Evaluation, Mission vs. Margin: Misaligned Incentives in the 340B Drug Pricing Program |
|
|
The Bottom Line
The attestation, the lawsuit and the 340B brief all land on the same question in your vendor paperwork: what your administrator owes you, and what it is allowed to keep to itself. Two of them live in your administrative services agreement and the third lives in your rebate guarantee. Two of them also carry a date you control, because you can file the attestation before the year closes and put a data request in your administrator's hands this month, while the 340B brief carries no deadline at all. The lawsuit is the reminder that employers with real bargaining power concluded a contract clause was not enough and went to a judge, so read your own clause now, while your 2027 paperwork is still open.
|
|
|
Jude Odu
Founder and Principal, Model Optimal Care
Author of Model Optimal Care: End U.S. Healthcare Waste, One Health Plan at a Time
|
|
|
|